HELEN TOLAR

MEHLMAN CONSULTING, INC. · WASHINGTON, DC · registered since 2024

Registered · LDAActive

Send proposal →Contact →Claim this profile →

At a glance

Registered since

2024

Senate LDA system

Clients

121

last 3 years

Filings

348

33 agencies contacted

Activity

filings by quarter

Works on

Taxation/Internal Revenue Code 122 Medicare/Medicaid 115 Health Issues 114 Budget/Appropriations 84 Trade (domestic/foreign) 74 Computer Industry 56 Environment/Superfund 52 Consumer Issues/Safety/Products 43 Energy/Nuclear 39 Labor Issues/Antitrust/Workplace 30 Pharmacy 29 Telecommunications 29 Veterans 28 Defense 27 Financial Institutions/Investments/Securities 24 Manufacturing 24 Insurance 19 Homeland Security 16 Aviation/Airlines/Airports 14 Housing 13 Communications/Broadcasting/Radio/TV 12 Immigration 12 Banking 11 Agriculture 9 Science/Technology 9 Copyright/Patent/Trademark 9 Small Business 8 Foreign Relations 7 Retirement 6 Utilities 6 Government Issues 5 Intelligence 4 Transportation 4 Accounting 3 Education 3 Clean Air and Water (quality) 3 Fuel/Gas/Oil 3 Civil Rights/Civil Liberties 3 Indian/Native American Affairs 3 Chemicals/Chemical Industry 3 Postal 3 Railroads 3 Automotive Industry 3 Animals 3 Trucking/Shipping 3 Law Enforcement/Crime/Criminal Justice 2 Economics/Economic Development 2 Food Industry (safety, labeling, etc.) 2 Marine/Maritime/Boating/Fisheries 2 Urban Development/Municipalities 1

Background

Government experience

CoS

Senator Boozman); Staff Dir/Chief Csl - House VA C (Rep. Miller); Prof Staff/Csl - Senate VA C (Senator Craig); Csl/LD (Rep. Miller); LA (Rep. Miller); Scheduler (Rep. Miller); Law Clerk (House Trans/Infra C

Disclosed on LD-2 filings

Career

MEHLMAN CONSULTING, INC.

WASHINGTON, DC

2024 - present

Specific issues

Implementation of Inflation Reduction Act of 2022.

Health Issues · 2024 Q3

S. 775 - Increasing Transparency in Generic Drug Applications Act. Issues related to pharmaceutical manufacturing domestic supply chain, in H.R. 8070 - National Defense Authorization Act. S.2220 - PREVAIL Act. S.4097 - PERA Act.

Pharmacy · 2024 Q3

EPA's proposed interim decision draft risk assessment for ethylene oxide.

Environment/Superfund · 2024 Q4

Issues related to freight, rail, and supply chain.

Transportation · 2024 Q4

Federal lobbying related to tax policy.

Taxation/Internal Revenue Code · 2024 Q4

Intellectual property protection.